Vu H Duong

15PUBLICATIONS
74CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsHaematological tumoursPredictive and prognostic markersMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 28, 2026
OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

|Jul 03, 2026
Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

|Nov 27, 2024
Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia.

Joseph F Mort, David Brighton, Samantha DiBenedetto

|Oct 22, 2024
A phase 1 study of the amino acid modulator pegcrisantaspase and venetoclax for relapsed or refractory acute myeloid leukemia.

Yuchen Liu, Dominique R Bollino, Osman M Bah

|Aug 07, 2024
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.

Fieke W Hoff, William G Blum, Ying Huang

|Apr 20, 2023
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.

Vu H Duong, Amy S Ruppert, Alice S Mims

Pageof 3

Frequent Collaborators

5 joint publications

Tara L Lin

5 joint publications

Joshua F Zeidner

4 joint publications

Yazan F Madanat

4 joint publications

Alice S Mims